BioXcel Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $642,000 | $2.3M | $1.4M | $375,000 | — |
| Operating income | -$50.5M | -$67.2M | -$171.8M | -$159.6M | -$106.9M |
| Operating expenses | — | — | — | — | $106.9M |
| Cost of revenue | $164,000 | $2.1M | $1.3M | $20,000 | — |
| Cash from operations | -$57.6M | -$72.0M | -$155.0M | -$135.3M | -$82.2M |
| Capital expenditure | $0 | $0 | $20,000 | $139,000 | $445,000 |
| Free cash flow | -$57.6M | -$72.0M | -$155.0M | -$135.5M | -$82.6M |
| Total assets | $44.9M | $38.3M | $73.7M | $205.9M | $239.4M |
| Total liabilities | $140.4M | $131.4M | $130.2M | $129.1M | $17.8M |
| Total debt | $112.2M | $106.7M | $102.7M | $101.4M | — |
Shares outstanding 30.9M
Annual filing data through FY ended December 31, 2025; float as of July 2, 2026.